Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/25/2010US20100048689 Process of obtainment of soy isoflavones
02/25/2010US20100048688 Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses
02/25/2010US20100048687 Use of phosphatase inhibitors for the treatment of neurodegenerative diseases
02/25/2010US20100048685 Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
02/25/2010US20100048684 EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF
02/25/2010US20100048683 Modified vaccinia virus ankara for the vaccination of neonates
02/25/2010US20100048682 Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
02/25/2010US20100048681 MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Acute Myeloid Leukemia (AML)
02/25/2010US20100048680 Alpha-1-Antitrypsin Variants and Uses Thereof
02/25/2010US20100048679 Polynucleotide therapy
02/25/2010US20100048678 Nucleic acids and polypeptides that are useful in controlling neuronal regeneration
02/25/2010US20100048677 Regulation of Integrin Surface Expression
02/25/2010US20100048676 Non-androgen dependent roles for androgen receptor in liver cancer
02/25/2010US20100048675 miRNA TRIPLEX FORMATIONS FOR THE DOWNREGULATION OF VIRAL REPLICATION
02/25/2010US20100048674 Role of miRNA in T cell leukemia
02/25/2010US20100048673 Oligonucleotides affecting expression of phosphodiesterases
02/25/2010US20100048671 Inhibition of the 44 kilodalton isoform of pim-1 kinase restores apoptosis induced by chemotherapeutic drugs in cancer cells
02/25/2010US20100048670 Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof
02/25/2010US20100048669 Therapeutic compounds
02/25/2010US20100048668 Compositions and methods to control abnormal cell growth
02/25/2010US20100048667 Thiolactones
02/25/2010US20100048666 Novel phenylacetic acid derivative
02/25/2010US20100048665 3-aminopyrrolidone derivatives
02/25/2010US20100048664 Therapeutic substituted pyrroles
02/25/2010US20100048663 Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents
02/25/2010US20100048662 Novel Pyrone-Indole Derivatives and Process for Their Preparation
02/25/2010US20100048660 Treatment of duchenne muscular dystrophy
02/25/2010US20100048659 Aqueous compositions containing metronidazole
02/25/2010US20100048658 Fused heterocyclic compounds
02/25/2010US20100048657 Control of malignant cells proliferation through the inhibition of casein kinase 2
02/25/2010US20100048656 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
02/25/2010US20100048654 Use of valsartan or its metabolite to in hibit platelet aggregation
02/25/2010US20100048653 Neuroprotective modulation of nmda receptor subtype activities
02/25/2010US20100048651 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
02/25/2010US20100048650 Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery
02/25/2010US20100048649 Combinations comprising bicyclic s1p lyase inhibitors
02/25/2010US20100048648 Thiophene derivatives as S1P1/EDGE1 receptor agonists
02/25/2010US20100048645 Solubilizing of metronidazole
02/25/2010US20100048644 Use of composition comprising amlodipine in preparing medicaments for treating a lower urinary tract disorder
02/25/2010US20100048643 Novel Polymorph Forms Of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
02/25/2010US20100048642 Methods for treating cognitive disorders
02/25/2010US20100048641 Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases
02/25/2010US20100048639 Oxadiazole derivates as s1p1 receptor agonists
02/25/2010US20100048638 Heparan sulfate inhibitors
02/25/2010US20100048637 Cyclohexylamines, phenylamines and uses thereof
02/25/2010US20100048636 Aspartic Protease Inhibitors
02/25/2010US20100048635 Use of collismycin and derivatives thereof as oxidative stress inhibitors
02/25/2010US20100048634 Method for treating apathy syndrome
02/25/2010US20100048633 Piperidine-4-acrylamides
02/25/2010US20100048632 Piperidine GPCR Agonists
02/25/2010US20100048631 Piperidine GPCR Agonists
02/25/2010US20100048630 Methods for treating cns disorders
02/25/2010US20100048629 Methods for treating neuropathic pain
02/25/2010US20100048628 Method for suppressing discoloration over time of adhesive preparation containing donepezil
02/25/2010US20100048627 synergistic pharmaceutical combination for the prevention or treatment of diabetes
02/25/2010US20100048626 Aryl Substituted Pyridines and the Use Thereof
02/25/2010US20100048625 Piperidine gpcr agonists
02/25/2010US20100048624 Use of piperidine derivatives as dermo-decontracting agents
02/25/2010US20100048623 Piperidines and related compounds for the treatment of alzheimer's disease
02/25/2010US20100048622 Crystalline forms of a biphenyl compound
02/25/2010US20100048621 Medicament for treating chronic obstructive pulmonary disease
02/25/2010US20100048620 Composition for treatment of undifferentiated gastric cancer
02/25/2010US20100048619 Cold Menthol Receptor Antagonists
02/25/2010US20100048618 Derivatives of 8-epiblechnic Acid and their Effects on Down-Regulation of Endothelin (ETA) receptor mRNA
02/25/2010US20100048617 Compounds
02/25/2010US20100048616 Combinations comprising antimuscarinic agents and pde4 inhibitors
02/25/2010US20100048615 Combinations comprising antimuscarinic agents and pde4 inhibitors
02/25/2010US20100048614 Therapeutic uses of bicyclic ligands of sigma 2 receptor
02/25/2010US20100048613 Polymorphic form of granisetron hydrochloride and methods of making the same
02/25/2010US20100048612 [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents
02/25/2010US20100048611 Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof
02/25/2010US20100048610 Carbinol derivatives having cyclic linker
02/25/2010US20100048609 Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
02/25/2010US20100048608 Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases
02/25/2010US20100048607 Formulations comprising palonosetron
02/25/2010US20100048606 10-Substituted Cytisine Derivatives and Methods of Use Thereof
02/25/2010US20100048605 Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
02/25/2010US20100048604 Ligands for Aldoketoreductases
02/25/2010US20100048603 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
02/25/2010US20100048602 Oligomer-Opioid Agonist Conjugates
02/25/2010US20100048601 HYDROCHLORIDE SALTS OF 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one AND PREPARATION PROCESS THEREFOR
02/25/2010US20100048600 such as trans-2-[3'-oxospiro [cyclohexane- 1,1'(3'H)-isobenzofuran]-4yl]-5-(2-pyridyl) imidazo[4,5-b]pyridine, exhibiting neuropeptide Y antagonistic effects, used for the treatment of cardiovascular, nervous system, metabolic, gastrointestinal, sexual and respiratory system disorders; pharmacokinetics
02/25/2010US20100048599 Compounds As Kinase Inhibitors
02/25/2010US20100048598 Topical compositions comprising 5-alpha reductase inhibitors
02/25/2010US20100048597 Organic Compounds and Their Uses
02/25/2010US20100048596 Indole Derivatives as Antitumoral Compounds
02/25/2010US20100048595 Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
02/25/2010US20100048594 Use of cytohesin inhibitors for chemically inducing longevity
02/25/2010US20100048593 Deazaflavin compounds and methods of use thereof
02/25/2010US20100048592 Use of sodium channel blockers for the management of musculoskeletal pain
02/25/2010US20100048591 Chemical compounds and processes
02/25/2010US20100048590 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
02/25/2010US20100048589 Cold Menthol Receptor Antagonists
02/25/2010US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
02/25/2010US20100048587 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
02/25/2010US20100048586 Multifunctional bioactive compounds
02/25/2010US20100048585 Quinoline derivatives as antibacterial agents
02/25/2010US20100048584 Pyridyl derivatives and their use as therapeutic agents
02/25/2010US20100048583 Novel Heterocyclic NF-kB Inhibitors
02/25/2010US20100048582 Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
1 ... 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 ... 7860